Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Rheumatology: Biosimilars are here to stay

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Morphological characteristics of sacroiliac joint MRI lesions in axial spondyloarthritis and control subjects

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Walter P Maksymowych
  • Mikkel Østergaard
  • Robert Landewé
  • William Barchuk
  • Ke Liu
  • Chantal Tasset
  • Leen Gilles
  • Thijs Hendrikx
  • Robin Besuyen
  • Xenofon Baraliakos
Vis graf over relationer

OBJECTIVE: To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial.

METHODS: Adults with active AS and inadequate response/intolerance to two or more NSAIDs were randomized 1:1 to filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, T1-weighted MRI scans of the SI joint were evaluated by two independent readers using Spondyloarthritis Research Consortium of Canada (SPARCC) Sacroiliac Joint Structural Score (SSS) definitions for erosion, backfill, fat metaplasia and ankylosis. Correlations between SPARCC SSS and improvement in clinical outcomes were also assessed.

RESULTS: MRI scans from 87 patients (48 filgotinib, 39 placebo) were evaluated. At baseline there were no notable differences between filgotinib and placebo for any MRI structural lesion types. From baseline to week 12, filgotinib was associated with a significant reduction in SI joint erosion score (P = 0.02) and an increase in backfill score (P = 0.005) vs placebo, with no significant between-group differences for ankylosis (P = 0.46) or fat metaplasia (P = 0.17). At week 12, the change in SPARCC MRI SI joint inflammation scores correlated positively with erosion scores but negatively with backfill scores.

CONCLUSION: The significant changes in MRI structural lesions induced by filgotinib in the SI joint by week 12 demonstrate that tissue repair can be observed very soon after starting treatment with a JAK1 preferential inhibitor. This could have prognostic implications for development of ankylosis.

TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03117270.

OriginalsprogEngelsk
TidsskriftRheumatology (Oxford, England)
Vol/bind61
Udgave nummer5
Sider (fra-til)2063-2071
Antal sider9
ISSN1462-0324
DOI
StatusUdgivet - 5 maj 2022

Bibliografisk note

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

ID: 70405885